Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | SHMT1 | P34896 | 3/20 | 0.58 |
| ▸ | SHMT2 | P34897 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8424253 | 0.86 | TP53 (0.60) | KDM4EALDH1A1GAALMNAHPGD | |
| SCHEMBL20255445 | 0.86 | SHMT2 (0.74) | KDM4EALDH1A1GAALMNAHPGD | |
| SCHEMBL12851276 | 0.86 | KDM4E (0.74) | KDM4EALDH1A1GAALMNAHPGD | |
| SCHEMBL21560130 | 0.84 | KDM4E (0.64) | KDM4EALDH1A1GAALMNAHPGD | |
| SCHEMBL8233766 | 0.83 | KDM4E (0.75) | KDM4EALDH1A1GAALMNAHPGD | |
| SCHEMBL14087050 | 0.81 | KDM4E (0.67) | KDM4EALDH1A1GAALMNAHPGD | |
| SCHEMBL1422234 | 0.81 | LMNA (0.74) | KDM4EALDH1A1GAALMNAHPGD | |
| SCHEMBL20255827 | 0.80 | KDM4E (0.62) | KDM4EALDH1A1GAALMNAHPGD | |
| SCHEMBL20255810 | 0.80 | SHMT2 (0.79) | KDM4EALDH1A1GAALMNAHPGD | |
| SCHEMBL21560128 | 0.80 | SHMT1 (0.70) | KDM4EALDH1A1GAALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335725-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20050203006-A1 | Novel lipopeptides as antibacterial agents | MERCK SHARP & DOHME CORP. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203006-A1 | Novel lipopeptides as antibacterial agents | CLPTM1, NGLY1, VIP | KDM4E 4432/4885ALDH1A1 4742/4885GAA 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.